{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:40:00Z","timestamp":1792143600933,"version":"4.4.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Metastatic castration-resistant prostate cancer has a poor prognosis especially when harboring DNA damage repair gene mutations, nevertheless, in the case of pathogenic <jats:italic toggle=\"yes\">BRCA<\/jats:italic> gene mutations, PARPi demonstrated a survival benefit and is a validated treatment. Nowadays, there is no data regarding unusual metastases after these drugs. Cutaneous metastases appear rarely in prostate cancer and were associated with a worse prognosis. Moreover, there are no consolidated data concerning skin tropism of prostate cancer cells, neither in the case of BRCA-associated cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Here, we report the case of a patient with a long history of BRCA1-mutated metastatic castration-resistant prostate cancer who developed a skin lesion on the scalp while on his fifth line of systemic therapy with olaparib. After a complete radical surgical excision, the pathology report showed prostate cancer localization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>A diagnosis of skin metastasis from prostate cancer was reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient then continued olaparib therapy; after 7 months from excision, he experienced further bone and biochemical progression but not cutaneous progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>A literature review of all reported cases of cutaneous metastasis in prostate cancer was conducted to shed light on the incidence, clinical presentation, diagnosis, treatment, and prognosis of this entity. We also reviewed published cases of skin metastasis in BRCA-associated cancers with an effort to correlate skin involvement with PARPi treatment, BRCAness status, and prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040016","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T18:03:22Z","timestamp":1728929002000},"page":"e40016","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Skin metastasis of BRCA mutated prostate cancer: A case report and a brief review of literature"],"prefix":"10.1097","volume":"103","author":[{"given":"Salim","family":"Jubran","sequence":"first","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Milani","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Erbetta","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pittarello","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Cavasin","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"},{"name":"Oncology Unit 3, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stragliotto","sequence":"additional","affiliation":[{"name":"Oncology Unit 3, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierantoni","sequence":"additional","affiliation":[{"name":"Oncology Unit 3, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Zampiva","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"},{"name":"Department of Engineering for Innovation Medicine (DIMI), Section of Innovation Biomedicine \u2013 Oncology Area, University of Verona, Verona, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-9249","authenticated-orcid":false,"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[{"name":"Oncology Unit 1, Istituto Oncologico Veneto, IOV \u2013 IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer.","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer.","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1568009623666230209121732","article-title":"Advances in ovarian cancer treatment beyond PARP inhibitors.","volume":"23","author":"Aliyuda","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4986365","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: prognostic and predictive implications.","volume":"2020","author":"Messina","year":"2020","journal-title":"J Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1162644","DOI":"10.3389\/fonc.2023.1162644","article-title":"Impact of DNA damage repair alterations on prostate cancer progression and metastasis.","volume":"13","author":"Lukashchuk","year":"2023","journal-title":"Front Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology.","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer.","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"9783","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic.","volume":"22","author":"Ghose","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer.","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP inhibitors in advanced prostate cancer.","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis.","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.SMJ.0000053676.73249.E5","article-title":"Cutaneous metastasis: a meta-analysis of data.","volume":"96","author":"Krathen","year":"2003","journal-title":"South Med J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.urology.2004.01.014","article-title":"Cutaneous metastases from genitourinary malignancies.","volume":"63","author":"Mueller","year":"2004","journal-title":"Urology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.cpccr.2022.100175","article-title":"Cutaneous metastasis from prostate cancer: a case report with literature review.","volume":"7","author":"Sharma","year":"2022","journal-title":"Curr Problems Cancer: Case Rep"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"doj_21544","DOI":"10.5070\/D3202021544","article-title":"Eruptive nodules of the head and neck: a case report of metastatic prostate cancer.","volume":"20","author":"Brown","year":"2014","journal-title":"Dermatol Online J"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1096-9098(199606)62:2<144::AID-JSO12>3.0.CO;2-8","article-title":"Cutaneous metastases from prostatic carcinoma.","volume":"62","author":"Piqu\u00e9 Duran","year":"1996","journal-title":"J Surg Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2133.2006.07696.x","article-title":"Telangiectatic cutaneous metastasis from carcinoma of the prostate.","volume":"156","author":"Reddy","year":"2007","journal-title":"Br J Dermatol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/cup.12296","article-title":"Cutaneous metastasis of prostate cancer: a case report and review of the literature with bioinformatics analysis of multiple healthcare delivery networks.","volume":"41","author":"Brown","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/j.ad.2015.09.021","article-title":"Distant cutaneous metastases of prostate cancer: a report of 2 cases.","volume":"107","author":"Rodr\u00edguez-Lojo","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1600-0560.2011.01677.x","article-title":"Cutaneous metastasis of prostatic adenocarcinoma: a cautionary tale.","volume":"38","author":"Rattanasirivilai","year":"2011","journal-title":"J Cutan Pathol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-0560.2007.00873.x","article-title":"Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature.","volume":"35","author":"Wang","year":"2008","journal-title":"J Cutan Pathol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1346-8138.2006.00009.x","article-title":"A case of Sister Mary Joseph\u2019s nodule from prostatic cancer.","volume":"33","author":"Fukuda","year":"2006","journal-title":"J Dermatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-4632.2004.02503.x","article-title":"Cutaneous metastasis to the chest wall from prostate cancer.","volume":"45","author":"Wu","year":"2006","journal-title":"Int J Dermatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e36570","DOI":"10.1097\/MD.0000000000036570","article-title":"Scalp nodules as the first presentation of prostate cancer: a CARE-compliant article.","volume":"102","author":"Oh","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R29-20250504","first-page":"5265909","article-title":"A case of prostatic carcinoma manifesting as cutaneous facial nodule.","volume":"2018","author":"Esquivel-Pinto","year":"2018","journal-title":"Case Rep Urol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2324709621990769","DOI":"10.1177\/2324709621990769","article-title":"Cutaneous metastasis of prostate adenocarcinoma: a rare presentation of a common disease.","volume":"9","author":"Dills","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/DAD.0b013e31823069cf","article-title":"Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review.","volume":"34","author":"Alcaraz","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4103\/IJPM.IJPM_852_18","article-title":"Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas.","volume":"63","author":"Garudadri","year":"2020","journal-title":"Indian J Pathol Microbiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D32410041718","article-title":"A novel case of NKX3.1-positive metastatic cutaneous prostate cancer.","volume":"24","author":"Wong","year":"2018","journal-title":"Dermatol Online J"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.","volume":"15","author":"Mannweiler","year":"2009","journal-title":"Pathol Oncol Res"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2490-7-3","article-title":"Differential expression of CD10 in prostate cancer and its clinical implication.","volume":"7","author":"Dall\u2019Era","year":"2007","journal-title":"BMC Urol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1158\/1078-0432.CCR-1052-03","article-title":"Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.","volume":"10","author":"Li","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1089\/jpm.2007.9928","article-title":"Cutaneous metastases of prostate cancer.","volume":"10","author":"Bailey","year":"2007","journal-title":"J Palliat Med"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1756-0500-7-505","article-title":"Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation.","volume":"7","author":"Mak","year":"2014","journal-title":"BMC Res Notes"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/RLU.0000000000004817","article-title":"68Ga-PSMA PET\/CT images of multiple cutaneous metastases in a patient with prostate carcinoma: complete response to 177Lu-PSMA-617 treatment.","volume":"48","author":"Sivrikoz","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R40-20250504","first-page":"46219","article-title":"Cutaneous metastases in progressive prostate adenocarcinoma: a case report and literature review.","volume":"15","author":"Brito","year":"2023","journal-title":"Cureus"},{"key":"R41-20250504","first-page":"1310","article-title":"Survie apr\u00e8s m\u00e9tastases cutan\u00e9es: \u00e9tude de 200 cas [Survival after cutaneous metastasis: a study of 200 cases].","volume":"128","author":"Schoenlaub","year":"2001","journal-title":"Ann Dermatol Venereol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0090-4295(80)90152-1","article-title":"Long\u2013term survival with skin metastases from carcinoma of prostate.","volume":"16","author":"Marquis","year":"1980","journal-title":"Urology"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5227\/skincancer.14.259","article-title":"A case of skin metastasis of prostate cancer responding well to hormone therapy (in Japanese).","volume":"14","author":"Miyazaki","year":"1999","journal-title":"Skin Cancer"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/ua.ua_102_22","article-title":"Cutaneous metastasis of castration-resistant prostate cancer: a rare case report and review of literature.","volume":"15","author":"Sarangi","year":"2023","journal-title":"Urol Ann"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5468\/ogs.2017.60.5.477","article-title":"BRCA1-mutated ovarian cancer with skin metastasis: a case report.","volume":"60","author":"Oh","year":"2017","journal-title":"Obstet Gynecol Sci"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"e28712","DOI":"10.1097\/MD.0000000000028712","article-title":"Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: a case report and review of the literature.","volume":"101","author":"Nie","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1214660","DOI":"10.3389\/fonc.2023.1214660","article-title":"Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.","volume":"13","author":"Caputo","year":"2023","journal-title":"Front Oncol"},{"key":"R48-20250504","first-page":"e49600","article-title":"Somatic BRCA mutation in metastatic breast cancer.","volume":"15","author":"Minick","year":"2023","journal-title":"Cureus"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.07.042","article-title":"Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: two case reports and review of the literature.","volume":"157","author":"Assaf","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:19:35Z","timestamp":1746321575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":49,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040016","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}